European Heart Journal Advance Access published online on February 13, 2007
European Heart Journal, doi:10.1093/eurheartj/ehl509
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction
1 Department of Molecular Cardiology, Department of Internal Medicine III, University of Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
2 Institute for Transfusion Medicine and Immunohaematology, Red Cross Blood Donor Service BadenWürttembergHessen, Frankfurt am Main, Germany
Received 10 June 2006; revised 1 July 2006; accepted 12 January 2007.
* Corresponding author. Tel: +49 69 6301 6667; fax: +49 69 6301 7113. E-mail address: dimmeler{at}em.uni-frankfurt.de
AIMS: The recently published REPAIR-AMI and ASTAMI trial showed differences in contractile recovery of left ventricular function after infusion of bone marrow-derived cells in acute myocardial infarction. Since the trials used different protocols for cell isolation and storage (REPAIR-AMI: Ficoll, storage in X-vivo 10 medium plus serum; ASTAMI: Lymphoprep, storage in NaCl plus plasma), we compared the functional activity of BMC isolated by the two different protocols.
METHODS AND RESULTS: The recovery of total cell number, colony-forming units (CFU), and the number of mesenchymal stem cells were significantly reduced to 77 ± 4%, 83 ± 16%, and 65 ± 15%, respectively, when using the ASTAMI protocol compared with the REPAIR protocol. The capacity of the isolated BMC to migrate in response to stromal cell-derived factor 1 (SDF-1) was profoundly reduced when using the ASTAMI cell isolation procedure (42 ± 8% and 78 ± 3% reduction in healthy and CAD-patient cells, respectively). Finally, infusion of BMC into a hindlimb ischaemia model demonstrated a significantly blunted blood-flow-recovery by BMC isolated with the ASTAMI protocol (54 ± 6% of the effect obtained by REPAIR cells). Comparison of the individual steps identified the use of NaCl and plasma for cell storage as major factors for functional impairment of the BMC.
CONCLUSION: Cell isolation protocols have a major impact on the functional activity of bone marrow-derived progenitor cells. The assessment of cell number and viability may not entirely reflect the functional capacity of cells in vivo. Additional functional testing appears to be mandatory to assure proper cell function before embarking on clinical cell therapy trials.
Key Words: Cell therapy BMC Isolation protocols Invasion capacity REPAIR-AMI
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
F. H. Seeger, T. Rasper, M. Koyanagi, H. Fox, A. M. Zeiher, and S. Dimmeler CXCR4 Expression Determines Functional Activity of Bone Marrow-Derived Mononuclear Cells for Therapeutic Neovascularization in Acute Ischemia Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1802 - 1809. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Meyer, K. C. Wollert, J. Lotz, J. Pirr, U. Rager, P. Lippolt, A. Hahn, S. Fichtner, A. Schaefer, L. Arseniev, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial Eur. Heart J., September 22, 2009; (2009) ehp374v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-S. Li, M. Kubo, K. Ueda, M. Murakami, M. Ohshima, T. Kobayashi, T. Tanaka, B. Shirasawa, A. Mikamo, and K. Hamano Identification of Risk Factors Related to Poor Angiogenic Potency of Bone Marrow Cells From Different Patients Circulation, September 15, 2009; 120(11_suppl_1): S255 - S261. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Fischer-Rasokat, B. Assmus, F. H. Seeger, J. Honold, D. Leistner, S. Fichtlscherer, V. Schachinger, T. Tonn, H. Martin, S. Dimmeler, et al. A Pilot Trial to Assess Potential Effects of Selective Intracoronary Bone Marrow-Derived Progenitor Cell Infusion in Patients With Nonischemic Dilated Cardiomyopathy: Final 1-Year Results of the Transplantation of Progenitor Cells and Functional Regeneration Enhancement Pilot Trial in Patients With Nonischemic Dilated Cardiomyopathy Circ Heart Fail, September 1, 2009; 2(5): 417 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Brunskill, C. J. Hyde, C. J. Doree, S. M. Watt, and E. Martin-Rendon Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease Eur J Heart Fail, September 1, 2009; 11(9): 887 - 896. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Prokopi, G. Pula, U. Mayr, C. Devue, J. Gallagher, Q. Xiao, C. M. Boulanger, N. Westwood, C. Urbich, J. Willeit, et al. Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures Blood, July 16, 2009; 114(3): 723 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Hibbert, X. Ma, A. Pourdjabbar, E. Holm, K. Rayner, Y.-X. Chen, J. Sun, L. Filion, and E. R. O'Brien Inhibition of endothelial progenitor cell glycogen synthase kinase-3{beta} results in attenuated neointima formation and enhanced re-endothelialization after arterial injury Cardiovasc Res, July 1, 2009; 83(1): 16 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P Sieveking and M. K. Ng Cell therapies for therapeutic angiogenesis: back to the bench Vascular Medicine, May 1, 2009; 14(2): 153 - 166. [Abstract] [PDF] |
||||
![]() |
H. Q. Ly and S. Nattel Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle Circulation, April 7, 2009; 119(13): 1824 - 1831. [Full Text] [PDF] |
||||
![]() |
M. Tendera and W. Wojakowski Cell therapy--success does not come easy Eur. Heart J., March 2, 2009; 30(6): 640 - 641. [Full Text] [PDF] |
||||
![]() |
R. L Kao, W. Browder, and C. Li Cellular Cardiomyoplasty: What Have We Learned? Asian Cardiovasc Thorac Ann, January 1, 2009; 17(1): 89 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lunde and S. Aakhus Intracoronary injection of mononuclear bone marrow cells after acute myocardial infarction: lessons from the ASTAMI trial Eur. Heart J. Suppl., December 1, 2008; 10(suppl_K): K35 - K38. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wojakowski, M. Kucia, K. Milewski, B. Machalinski, M. Halasa, P. Buszman, P. Klimeczek, M. Kazmierski, M. Pasowicz, M. Z. Ratajczak, et al. The role of CXCR4/SDF-1, CD117/SCF, and c-met/HGF chemokine signalling in the mobilization of progenitor cells and the parameters of the left ventricular function, remodelling, and myocardial perfusion following acute myocardial infarction Eur. Heart J. Suppl., December 1, 2008; 10(suppl_K): K16 - K23. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Ward, J. Lavoie, and D. J. Stewart "B2 or not B2?": Kinin Receptors and Endothelial Progenitor Cell Dysfunction Circ. Res., November 21, 2008; 103(11): 1202 - 1203. [Full Text] [PDF] |
||||
![]() |
H. V. Huikuri, K. Kervinen, M. Niemela, K. Ylitalo, M. Saily, P. Koistinen, E.-R. Savolainen, H. Ukkonen, M. Pietila, J. K.E. Airaksinen, et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction Eur. Heart J., November 2, 2008; 29(22): 2723 - 2732. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Martin-Rendon, S. J. Brunskill, C. J. Hyde, S. J. Stanworth, A. Mathur, and S. M. Watt Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review Eur. Heart J., August 1, 2008; 29(15): 1807 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Carr, D. J. Stuckey, L. Tatton, D. J. Tyler, S. J. M. Hale, D. Sweeney, J. E. Schneider, E. Martin-Rendon, G. K. Radda, S. E. Harding, et al. Bone marrow-derived stromal cells home to and remain in the infarcted rat heart but fail to improve function: an in vivo cine-MRI study Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H533 - H542. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions Circulation, July 29, 2008; 118(5): 552 - 566. [Full Text] [PDF] |
||||
![]() |
A. C.P. Diederichsen, J. E. Moller, P. Thayssen, A. B. Junker, L. Videbaek, S. G. Saekmose, T. Barington, M. Kristiansen, and M. Kassem Effect of repeated intracoronary injection of bone marrow cells in patients with ischaemic heart failure The Danish Stem Cell study--Congestive Heart Failure trial (DanCell-CHF) Eur J Heart Fail, July 1, 2008; 10(7): 661 - 667. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zampetaki, J. P. Kirton, and Q. Xu Vascular repair by endothelial progenitor cells Cardiovasc Res, June 1, 2008; 78(3): 413 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hinkel, C. El-Aouni, T. Olson, J. Horstkotte, S. Mayer, S. Muller;, M. Willhauck, C. Spitzweg, F.-J. Gildehaus, W. Munzing, et al. Thymosin {beta}4 Is an Essential Paracrine Factor of Embryonic Endothelial Progenitor Cell-Mediated Cardioprotection Circulation, April 29, 2008; 117(17): 2232 - 2240. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Lunde, S. Solheim, K. Forfang, H. Arnesen, L. Brinch, R. Bjornerheim, A. Ragnarsson, T. Egeland, K. Endresen, A. Ilebekk, et al. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 674 - 676. [Full Text] [PDF] |
||||
![]() |
M. Rota, J. Kajstura, T. Hosoda, C. Bearzi, S. Vitale, G. Esposito, G. Iaffaldano, M. E. Padin-Iruegas, A. Gonzalez, R. Rizzi, et al. Bone marrow cells adopt the cardiomyogenic fate in vivo PNAS, November 6, 2007; 104(45): 17783 - 17788. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lipinski, G. G.L. Biondi-Zoccai, A. Abbate, R. Khianey, I. Sheiban, J. Bartunek, M. Vanderheyden, H.-S. Kim, H.-J. Kang, B. E. Strauer, et al. Impact of Intracoronary Cell Therapy on Left Ventricular Function in the Setting of Acute Myocardial Infarction: A Collaborative Systematic Review and Meta-Analysis of Controlled Clinical Trials J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1761 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Egeland and J. E. Brinchmann The REPAIR-AMI and ASTAMI trials: cell isolation procedures Eur. Heart J., September 1, 2007; 28(17): 2174 - 2175. [Full Text] [PDF] |
||||
![]() |
A. M. Zeiher, V. Schachinger, S. Dimmeler, and For the REPAIR-AMI Investigators Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial: reply Eur. Heart J., September 1, 2007; 28(17): 2173 - 2174. [Full Text] [PDF] |
||||
![]() |
S. Erbs, A. Linke, V. Schachinger, B. Assmus, H. Thiele, K.-W. Diederich, C. Hoffmann, S. Dimmeler, T. Tonn, R. Hambrecht, et al. Restoration of Microvascular Function in the Infarct-Related Artery by Intracoronary Transplantation of Bone Marrow Progenitor Cells in Patients With Acute Myocardial Infarction: The Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) Trial Circulation, July 24, 2007; 116(4): 366 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Assmus, U. Fischer-Rasokat, J. Honold, F. H. Seeger, S. Fichtlscherer, T. Tonn, E. Seifried, V. Schachinger, S. Dimmeler, and A. M. Zeiher Transcoronary Transplantation of Functionally Competent BMCs Is Associated With a Decrease in Natriuretic Peptide Serum Levels and Improved Survival of Patients With Chronic Postinfarction Heart Failure: Results of the TOPCARE-CHD Registry Circ. Res., April 27, 2007; 100(8): 1234 - 1241. [Abstract] [Full Text] [PDF] |
||||














